Search

Byline: L. Schaade (1), C.A. Platzer (1), M. Kleines (1), K. Ritter (1) Keywords: Key words GB virus C; Hepatitis G virus; Hepatitis; Malignancy Abstract: GB virus C/hepatitis G virus (GBV-C/HGV) is a recently discovered flavivirus of still unknown pathogenic relevance. We examined traumatologic outpatients to determine GBV-C/HGV viremia for further epidemiological studies, as blood donors hitherto used as controls represent healthy individuals without risk factors. Anti-GBV-C/HGV antibodies were detectable in 13.2% (95% confidence interval [CI] 9.3--18.2) and GBV-C/HGV RNA was detectable in 4.5% (95% CI 2.4--8.2) of the outpatients. In chronic non-A-E hepatitis patients GBV-C/HGV viremia was detectable at a significantly higher level of 16.1% (95% CI 6.1--:34.5), while the prevalence of anti-GBV-C/HGV antibodies was 12.9% (95% CI 4.2--30.8). The rate of GBV-C/HGV viremia in patients with malignant diseases (different types of tumors, blood recipients were excluded) was 12.5% (95% CI 8.4-- 18.1), a significant elevation compared to traumatologic outpatients. The seroprevalence in the tumor group was 22.1% (95% CI 16.7--28.6), also significantly elevated. Thus, there are two messages. Firstly, testing for GBV-C/HGV may be a useful extension of the diagnostic procedure of viral hepatitis. Secondly, common risk factors or etiologic relations of GBV-C/HGV and extrahepatic malignancies should be discussed. Author Affiliation: (1) Institute for Medical Microbiology, Dept. of Virology, Technical University of the Rhineland and Westphalia Aachen, Pauwelsstr. 30, D-52074 Aachen, Germany Phone: +49-241-8088460, Fax: +49-241-8888483, DE Article note: Received: March 29, 1999 * Revision accepted: November 22, 1999

GB virus C/hepatitis G virus (GBV-C/HGV) is a recently discovered flavivirus of still unknown pathogenic relevance. We examined traumatologic outpatients to determine GBV-C/HGV viremia for further epidemiological studies, as blood donors hitherto used as controls represent healthy individuals without risk factors. Anti- GBV-C/HGV antibodies were detectable in 13.2% (95% confidence interval [Cl] 9.3-18.2) and GBV-C/HGV RNA was detectable in 45% (95% Cl 2.4-8.2) of the outpatients. In chronic non-A-E hepatitis patients GBV-C/HGV viremia was detectable at a significantly higher level of 16.1% (95% Cl 6.1-34.5), while the prevalence of anti-GBV-C/HGV antibodies was 12.9% (95% Cl 4.2-30.8). The rate of GBV-C/HGV viremia in patients with malignant diseases (different types of tumors, blood recipients were excluded) was 12.5% (95% Cl 8.4-18.1), a significant elevation compared to traumatologic outpatients. The seroprevalence in the tumor group was 22.1% (95% Cl 16.7-28.6), also significantly elevated. Thus, there are two messages. Firstly, testing for GBV-C/HGV may be a useful extension of the diagnostic procedure of viral hepatitis. Secondly, common risk factors or etiologic relations of GBV-C/HGV and extrahepatic malignancies should be discussed. [ABSTRACT FROM AUTHOR]